{
  "chapter": "Anticancer Drugs-Cytotoxic Drugs",
  "questions": [
    {
      "q_no": 1,
      "question": "A 65-year-old male presents with a recent diagnosis of advanced non-small cell lung cancer (NSCLC). The oncologist decides to initiate treatment with pemetrexed. The patient has a history of COPD and hypertension, which are well-controlled with medication. Which of the following best describes the mechanism of action of pemetrexed in the treatment of non-small cell lung cancer (NSCLC)? formyltransferase, thereby disrupting DNA and RNA synthesis.",
      "options": {
        "A": "Inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide",
        "B": "Binds to tubulin, inhibiting microtubule formation and causing cell cycle arrest in the M phase.",
        "C": "Acts as an alkylating agent, causing cross-linking of DNA strands and preventing DNA replication.",
        "D": "Inhibits topoisomerase II, leading to DNA strand breaks and apoptosis."
      },
      "correct_answer": "A",
      "explanation": "ribonucleotide formyltransferase, thereby disrupting DNA and RNA synthesis. Correct Answer: A) Inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, thereby disrupting DNA and RNA synthesis. Explanation: Pemetrexed is a folate analogue used in the treatment of various cancers, including non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. It works by inhibiting several key enzymes involved in folate metabolism and nucleotide synthesis which disrupts DNA and RNA synthesis, leading to the inhibition of cancer cell growth and proliferation. Trials for the treatment regimens of non-small cell lung cancer (NSCLC): JMDB Trial PARAMOUNT Trial LUX-Lung Trials Mechanism of Action of Folate Analogues: Folate Analogue Mechanism of Action Uses Pemetrexed Inhibition of Thymidylate synthase Dihydrofolate reductase Glycinamide ribonucleotide formyltransferase (GARFT) → depletion of nucleotide pools essential for DNA synthesis and repair. Mesothelioma Non-small cell lung cancer (NSCLC) In combination with cisplatin for malignant pleural mesothelioma. Methotrexate Inhibition of dihydrofolate reductase - prevents the formation of THF. Disrupts DNA synthesis and cell proliferation. Acute lymphoblastic leukemia (ALL) Non-Hodgkin lymphoma Osteosarcoma Gestational trophoblastic neoplasia Rheumatoid arthritis Psoriasis. Raltitrexed Inhibition of thymidylate synthase - interfering with DNA synthesis. Colorectal cancer. Pralatrexate Competitive inhibitor of dihydrofolate reductase thymidylate synthase, → disrupting folate metabolism and inhibiting DNA synthesis. Relapsed or refractory peripheral T-cell lymphoma (PTCL).",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 2,
      "question": "Which of the following is true about Eribulin?",
      "options": {
        "A": "It is less affected by the PGP efflux pump",
        "B": "Used in colorectal cancer",
        "C": "Inhibits depolymerization of microtubule",
        "D": "Forms toxic metabolite called SN-38 causing GIT damage"
      },
      "correct_answer": "A",
      "explanation": "Correct answer: A) It is less affected by the PGP efflux pump Explanation : Eribulin less affected by the PGP efflux pump than other microtubule disruptors, making it effective in drug-resistant tumors that overexpress PGP. Eribulin is used to treat drug-resistant metastatic breast cancer and liposarcoma. (Option B Ruled out) Eribulin works by binding to the vinca site on β -tubulin and inhibiting polymerization of the microtubule assembly. (Option C Ruled out) Irinotecan, a Topoisomerase I inhibitor, forms a toxic metabolite called SN-38 causing GIT damage. (Option D Ruled out) Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1364, 1366",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 3,
      "question": "A 55-year-old male patient undergoing treatment for testicular cancer develops pruritic, erythematous bands on his arms and back. What is the mechanism of action of the drug that causes this cutaneous presentation?",
      "options": {
        "A": "Generates free radicals and induces DNA cleavage via deoxyribose ring damage",
        "B": "Inhibits ribonucleotide reductase",
        "C": "Prevents polymerization and disrupts microtubule formation",
        "D": "Inhibits topoisomerase II"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Generates free radicals and induces DNA cleavage via deoxyribose ring damage chemotherapy regimens BEP (bleomycin, etoposide, and cisplatin) Bleomycin is known to cause a variety of cutaneous toxicities, including a rare side effect called flagellate pigmentation which presents as pruritic, erythematous bands on the arms, back, scalp, and hands and can be treated with topical corticosteroids. The mechanism of action of bleomycin is it binds to DNA to generate free radicals and induce DNA cleavage via deoxyribose ring damage in the G2 phase. Hydroxyurea inhibits ribonucleotide reductase (Option B) , blocking DNA synthesis Vinca alkaloids bind to tubulin, preventing polymerization and disrupting microtubule formation(Option C) Anthracyclines Inhibit topoisomerase II (Option D) acting on the G2 and S phase Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1363, 1367, 1368, 1370, 1372, 1377",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q3_q.png",
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 4,
      "question": "A 62-year-old female patient, receiving treatment with daunorubicin for breast cancer, presents with symptoms of fatigue, shortness of breath, and chest pain. An echocardiogram shows decreased left ventricular ejection fraction. Which of the following agents should be administered to prevent further cardiac damage?",
      "options": {
        "A": "Penicillamine",
        "B": "Dexrazoxane",
        "C": "Ethylenediaminetetraacetic acid (EDTA)",
        "D": "Dimercaprol"
      },
      "correct_answer": "B",
      "explanation": "peroxidation, which is promoted by Fe2+ causing Cardiomyopathy. Dexrazoxane is a cardioprotective, iron-chelating agent. It is used to prevent cardiotoxicity caused by the Anthracyclines like Daunorubicin and Doxorubicin. Dexrazoxane may also prevent anthracycline-derived DNA damage by interacting with topoisomerase II in cardiac cells. Penicillamine (Option A) is used for copper chelation and certain conditions like rheumatoid arthritis Dimercaprol (Option D) is used for arsenic and other heavy metal poisonings EDTA (Option C) is primarily used for lead poisoning. None of these agents provide the specific cardioprotective effects that dexrazoxane does against anthracycline-induced damage. Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1368",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 5,
      "question": "A 45 y/o female was recently diagnosed with acute promyelocytic leukemia (APML). She has been undergoing treatment for the same for the past 1 month. She now presents with sudden dyspnea, tachypnea & dry cough. O/E cyanosis is present. The doctor suspects ARDS. Her CBC showed elevated WBC counts as well. Which of the following drugs is responsible for the patient's condition?",
      "options": {
        "A": "All-trans retinoic acid (ATRA)",
        "B": "Methotrexate",
        "C": "Cyclophosphamide",
        "D": "Azathioprine"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) All-trans retinoic acid (ATRA) Explanation ATRA is the mainstay of treatment for APML. The patient’s elevated WBCs and presence of ARDS post-chemotherapy for her APML suggest she has developed Leukocyte maturation syndrome. While highly effective in inducing remission in APML patients, it can lead to a complication known as leukocytic maturation syndrome, also called retinoic acid syndrome (RAS) which is characterized by highly elevated leukocyte counts (sometimes even 50,000 to 100,000) and ARDS. RAS typically occurs within the first month of ATRA therapy and is managed by temporarily discontinuing ATRA and administering dexamethasone. Other side effects of ATRA include: Diabetes Dyslipidemia Infertility Mechanism of Action of All-Trans Retinoic Acid (ATRA) in APML: Methotrexate and Cyclophosphamide (Option B&C) is used to treat several leukemias, however, it is not typically associated with leukocytic maturation syndrome (retinoic acid syndrome) Azathioprine (Option D) is an immunosuppressive drug used in the treatment of various autoimmune diseases and in preventing organ rejection in transplant recipients. While azathioprine can cause bone marrow suppression and increase the risk of infections, it is not associated with leukocyte maturation syndrome. Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1372-1373",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q5_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 6,
      "question": "A 30 y/o male came with h/o testicular cancer. He underwent chemotherapy 6 months ago for the same. He now presents with progressive dyspnea and a dry cough for the past 3 months. Pulmonary function tests reveal restrictive lung disease with decreased lung volumes. Chest Xray shows diffuse basilar infiltrates and Pulmonary fibrosis. Which of the following chemotherapy drugs is most likely responsible for the patient's condition?",
      "options": {
        "A": "Cisplatin",
        "B": "Etoposide",
        "C": "Bleomycin",
        "D": "Methotrexate"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Bleomycin Explanation: The patient's signs, symptoms, and imaging studies suggest that he most likely has pulmonary fibrosis. This could be a result of the side effects of the drug bleomycin used in his chemotherapy regimen (BEP- Bleomycin, Etoposide, Cisplatin) Bleomycin is an antitumor antibiotic that is well-known for its association with pulmonary toxicity, including pulmonary fibrosis which occurs as follows: Cisplatin (Option A) is a platinum-based chemotherapy drug commonly used in the treatment of testicular cancer. Etoposide (Option B) is a topoisomerase II inhibitor used in the treatment of testicular cancer among other malignancies. Pulmonary fibrosis is not a recognized adverse effect of cisplatin and Etoposide Methotrexate (Option D) is a folate antagonist commonly used in the treatment of various malignancies, but it is not a standard component of chemotherapy regimens for testicular cancer. Pulmonary toxicity can occur with methotrexate, presenting as pneumonitis rather than fibrosis, and it is associated with high-dose or prolonged therapy used in conditions like rheumatoid arthritis or psoriasis. Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1370",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q6_exp.png",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 7,
      "question": "A 25-year-old male patient with a known history of Crigler-Najjar syndrome type I is diagnosed with metastatic colon cancer. The oncology team is planning his treatment regimen, which includes various anticancer drugs. Which of the following anti-cancer drugs is contraindicated in this patient?",
      "options": {
        "A": "Irinotecan",
        "B": "Topotecan",
        "C": "Etoposide",
        "D": "5 Fluro-Uracil"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Irinotecan Explanation: Irinotecan is a topoisomerase 1 inhibitor. Irinotecan forms a toxic metabolite called SN-38. that is eliminated by UGT1A1 Therefore, it is contraindicated in patients with Crigler-Najjar syndrome and Gilbert syndrome due to deficiency of UGT1A1. Topoisomerase inhibitors: Reference: Irinotecan & other drugs contraindicated in Crigler-Najjar syndrome",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q7_exp.png",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 8,
      "question": "A 55 y/o woman presents with a new diagnosis of metastatic breast cancer. Her oncologist decides to initiate treatment with a drug that inhibits microtubules. Considering her condition and the available microtubule- inhibiting drugs, the oncologist discusses the options, including vincristine, vinblastine, paclitaxel, and docetaxel. Which of the following statements is true for microtubule-inhibiting anti-cancer drugs? preventing the formation of microtubules. mitotic spindle dysfunction.",
      "options": {
        "A": "Vincristine & vinblastine are both vinca alkaloids that inhibit tubulin polymerization, thereby",
        "B": "Vincristine & vinblastine are both equally neurotoxic.",
        "C": "Paclitaxel and docetaxel both destabilize microtubules by inhibiting tubulin assembly, leading to",
        "D": "Paclitaxel and docetaxel are both contraindicated in liver disease"
      },
      "correct_answer": "A",
      "explanation": "polymerization, thereby preventing the formation of microtubules. Correct Answer: A) Vincristine & vinblastine are both vinca alkaloids that inhibit tubulin polymerization, thereby preventing the formation of microtubules. Explanation: Both vinblastine and vincristine are vinca alkaloids. These drugs bind to tubulin and inhibit its polymerization into microtubules, which prevents the formation of the mitotic spindle. The cell division is hence arrested at metaphase, effectively halting the proliferation of cancer cells. Vinca Alkaloids and Taxanes: Vinca Alkaloids Taxanes Mechanism Inhibit polymerization of microtubules Inhibit the formation of spindle Inhibit depolymerization of microtubules Inhibit movement or over-stabilization of spindle Drugs Vincristine Vinblastine Vinorelbine Vindesine Paclitaxel Docetaxel Cabazitaxel Toxicity Highly neurotoxic Causes paralytic ileus Produces foot drop Causes SIADH Causes glove and stocking neuropathy Highly neurotoxic Causes paralytic ileus Causes glove and stocking neuropathy Vincristine is more neurotoxic than vinblastine (Option B): Both of them disrupt microtubule dynamics by inhibiting tubulin polymerization, but vincristine does so more potently in neuronal cells. Microtubules are essential for axonal transport, a process critical for the movement of organelles, proteins, and other materials within neurons. Vincristine’s stronger disruption of this process leads to greater neurotoxicity. Both docetaxel and paclitaxel stabilize microtubules (Option C): They enhance the polymerization of tubulin and over-stabilize the microtubules, preventing their disassembly, which disrupts the normal dynamic equilibrium required for mitotic spindle function. Only Paclitaxel is contraindicated in liver disease whereas docetaxel is not (Option D): Paclitaxel is extensively metabolized by the liver, primarily through the cytochrome P450 enzyme system, specifically CYP2C8 and CYP3A4. In patients with liver disease, the metabolic capacity of the liver is significantly impaired leading to decreased clearance of paclitaxel from the body. This results in higher systemic concentrations of the drug, increasing the risk of toxicity. In contrast, docetaxel is a drug that gets excreted mainly via the kidneys, hence it is contraindicated in kidney disease. Reference: Goodman & Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1363-1365 KDT-Essentials of Medical Pharmacology, 8th Edition, Page 924-925",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 9,
      "question": "Which of the following purine analogues is considered the drug of choice (DOC) for treating hairy cell leukemia?",
      "options": {
        "A": "Thioguanine",
        "B": "Cladribine",
        "C": "Fludarabine",
        "D": "Mercaptopurine"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Cladribine Explanation Purine analogues are the DOC in various neoplastic conditions due to the following MOA: Enter the cell. Converted to fake nucleosides by HGPRTase enzyme (Hypoxanthine guanine phosphoribosyltransferase). Incorporated into DNA. Inhibits DNA polymerase enzyme. Inhibits DNA synthesis. Purine Analogues and their uses: Purine Analogue Uses Cladribine Hairy cell leukemia (DOC), multiple sclerosis Fludarabine (Option C -Ruled out) Chronic lymphocytic leukemia (CLL) [DOC], low-grade non-Hodgkin's lymphoma Mercaptopurine (Option D -Ruled out) Acute lymphoblastic leukemia (ALL) maintenance, inflammatory bowel disease (off-label) Thioguanine (Option A- Ruled out) Acute myeloid leukemia (AML) Pentostatin Hairy cell leukemia Azathioprine Organ transplantation, rheumatoid arthritis, IBD (DOC) and SLE (DOC) Nelarabine T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL) [DOC] Clofarabine Pediatric ALL (DOC) Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1360-1362",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 10,
      "question": "Match the following conditions and the pyrimidine analogues which are used as drugs of choice. a) Pancreatic cancer 1. Cytosine arabinoside b) Acute Myeloid Leukemia (AML) 2. Azacitidine c) Myelodysplastic syndrome 3. 5-Fluorouracil d) Colorectal Cancer 4. Gemcitabine",
      "options": {
        "A": "a) - 4; b) - 1; c) - 2; d) - 3",
        "B": "a) - 3; b) - 4; c) - 1; d) - 2",
        "C": "a) - 1; b) - 2; c) - 3; d) - 4",
        "D": "a) - 2; b) - 3; c) - 4; d) - 1"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) a) - 4; b) - 1; c) - 2; d) - 3 Explanation: Drug of Choices for given conditions are: Pancreatic cancer - Gemcitabine Acute Myeloid Leukemia (AML) - Cytosine arabinoside Myelodysplastic syndrome - Azacitidine Colorectal Cancer - 5- Fluorouracil Pyrimidine Analogues with uses: Pyrimidine Analogue Use(s) 5-Fluorouracil Colorectal cancer, breast cancer, other solid tumors Cytarabine (Cytosine arabinoside) Acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma Gemcitabine Pancreatic cancer (DOC), non-small cell lung cancer, bladder cancer Azacitidine and Decitabine Myelodysplastic syndromes (DOC), AML Capecitabine Colorectal cancer, breast cancer, gastric cancer Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1356-1360",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 11,
      "question": "A 55-year-old woman with metastatic breast cancer is undergoing chemotherapy. She presents with complaints of redness, swelling, and pain on her palms and soles. She describes a tingling sensation that has progressed to a burning pain over the past week. Upon physical examination, there is erythema and mild swelling of the affected areas, with some peeling of the skin as shown below. Her current chemotherapy regimen includes capecitabine and docetaxel. Which of the following is the most likely diagnosis for this patient's symptoms?",
      "options": {
        "A": "Erythromelalgia",
        "B": "Erythema multiforme",
        "C": "Hand-foot syndrome (palmar-plantar erythrodysesthesia)",
        "D": "Stevens-Johnson syndrome"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Hand-foot syndrome (palmar-plantar erythrodysesthesia) Explanation: This patient on chemotherapy with capecitabine and docetaxel has developed redness, swelling, and pain on her palms and soles and tingling sensation that has progressed to a burning pain. There is also mild swelling with some peeling of the skin. These symptoms point towards hand-foot syndrome. Hand-foot syndrome, also known as palmar-plantar erythrodysesthesia or acral erythema: Occurs due to the leakage of the chemotherapeutic drugs into the capillaries of the hands and feet, causing damage to the surrounding tissues. Initially presents with numbness, tingling, or burning pain in the palms and soles. Accompanied by sharply demarcated erythema (redness) which may or may not include edema (swelling), cracking, or desquamation (peeling skin). Blistering and ulceration seen in advanced cases Lateral parts and distal fat pads of the palms are often affected before the soles of the feet. Drugs causing Hand-foot syndrome: 5- Fluorouracil Capecitabine (maximum) Docetaxel Doxorubicin (including pegylated liposomal doxorubicin) Preventive management of Hand-foot syndrome: U se of pyridoxine (vitamin B6) has been recommended. Erythromelalgia (Option A): Characterized by episodes of red, hot, and painful extremities. Usually not associated with chemotherapy and does not typically cause skin peeling. Episodic presentation rather than continuous, which contrasts with the progressive and persistent symptoms seen in HFS.",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q11_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 12,
      "question": "A 55-year-old patient with colorectal cancer is being treated with 5-fluorouracil (5-FU) as part of their chemotherapy regimen. Which of the following best describes the mechanism by which 5-fluorouracil exerts its anti-cancer effects in this patient? termination. thymidylate synthase, leading to decreased thymidine production and inhibition of DNA synthesis.",
      "options": {
        "A": "5-Fluorouracil inhibits DNA synthesis by incorporating into the DNA strand and causing chain",
        "B": "5-Fluorouracil inhibits RNA polymerase, preventing the transcription of mRNA.",
        "C": "5-Fluorouracil is converted into fluorodeoxyuridine monophosphate (FdUMP), which inhibits",
        "D": "5-Fluorouracil activates topoisomerase I, causing breaks in DNA strands."
      },
      "correct_answer": "C",
      "explanation": "which inhibits thymidylate synthase, leading to decreased thymidine production and inhibition of DNA synthesis. Correct Answer: C) 5-Fluorouracil is converted into fluorodeoxyuridine monophosphate (FdUMP), which inhibits thymidylate synthase, leading to decreased thymidine production and inhibition of DNA synthesis. thymidine production and inhibition of DNA synthesis. It is always combined with THF to increase the effectiveness since THF increases binding of 5 fluorouracil with thymidylate synthase. Uses of 5-FU: Given IV for all GIT cancer along with platin Given in breast cancer Topical application on skin: For treatment of Mycosis Fungoides (Sezary Syndrome) Basal Cell Carcinoma Actinic Keratosis Capecitabine is an oral pro-drug approved for breast cancer treatment Colorectal cancer FOLFOX Regimen : Folinic acid , Fluorouracil (5-FU), Oxaliplatin FOLFIRINOX Regimen : Folinic acid, Fluorouracil (5-FU), Irinotecan, Oxaliplatin Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1356-1360",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q12_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 13,
      "question": "A 55-year-old woman with a history of rheumatoid arthritis under medication presents with complaints of fatigue, oral ulcers, and a non-productive cough. On examination, she appears pale, and reveals a temp of 100.9°F. Laboratory investigations show the following: Pancytopenia, elevated BUN and creatinine levels and elevated transaminases. Which of the following is the most likely diagnosis?",
      "options": {
        "A": "Systemic lupus erythematosus (SLE)",
        "B": "Methotrexate toxicity",
        "C": "Felty's syndrome",
        "D": "Acute viral hepatitis"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Methotrexate toxicity Explanation: The patient's presentation of fatigue, oral ulcers, fever, and pancytopenia along with elevated BUN and creatinine levels suggest methotrexate toxicity. Methotrexate Toxicity and Side Effects: Bone Marrow Suppression- Risk of spontaneous hemorrhage, life-threatening infection Megaloblastic anemia Alopecia and dermatitis Pneumonitis Nephrotoxicity (high doses) Defective oogenesis or spermatogenesis, abortion, and teratogenesis Hepatotoxic (Cirrhosis ) Intrathecal Administration of MTX Meningismus Inflammatory Response in CSF Seizures, coma, and rare cases of death. Management of Methotrexate Toxicity: 1. Stop methotrexate immediately. 2. Administer leucovorin : It is advised to monitor methotrexate levels to establish the correct dosage and duration for leucovorin rescue therapy. (Note: Leucovorin cannot reverse neurotoxicity) 3. Administer glucarpidase if serum methotrexate concentration is significantly elevated or persistent elevation with renal dysfunction. 4. Hydration and alkalinization : IV fluids with sodium bicarbonate to alkalinize urine and promote methotrexate excretion. 5. Hemodialysis 6. Supportive Care: Blood transfusions for significant anemia, Antibiotics for infections due to neutropenia, Platelet transfusions for significant thrombocytopenia. SLE (Option A) can present with fatigue, oral ulcers, fever, and hematological abnormalities (like anemia and leukopenia). However, SLE often has more specific findings such as a malar rash, photosensitivity, arthritis, serositis, and renal involvement (e.g., proteinuria). Felty's syndrome (Option C) is characterized by the triad of rheumatoid arthritis, splenomegaly, and neutropenia. Acute Viral Hepatitis (Option D) Although the patient has elevated liver enzymes and fever, the presence of oral ulcers, pancytopenia, and renal impairment are not typically associated with acute viral hepatitis. Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1353-1356",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 14,
      "question": "A 35-year-old female presents with vaginal bleeding, abdominal pain, and a high serum β -hCG level. Imaging studies and histopathology confirm a diagnosis of choriocarcinoma. The oncologist decides to start treatment with a chemotherapeutic agent. Which of the following drugs is most appropriate for this patient?",
      "options": {
        "A": "Cisplatin",
        "B": "Methotrexate",
        "C": "Doxorubicin",
        "D": "Vincristine"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Methotrexate Explanation Methotrexate has been shown to be curative and is the drug of choice for the treatment of choriocarcinoma. Mechanism of Action: Methotrexate is a folate antagonist that inhibits dihydrofolate reductase (DHFR) and thymidylate synthase, leading to inhibition of DNA synthesis. This action is most effective during the S phase of the cell cycle, where DNA replication occurs. Methotrexate (MTX) inhibits AICAR transformylase, disrupting purine synthesis. This leads to the accumulation of AICAR, which is converted to adenosine. Elevated adenosine levels exert anti-inflammatory effects by modulating immune responses, inhibiting lymphocyte activation, and reducing pro-inflammatory cytokine production. Efficacy in Choriocarcinoma: Methotrexate has been shown to be curative in choriocarcinoma. The typical dosage for choriocarcinoma is 15-30 mg/day for 5 days orally or 20-40 mg/m² BSA i.m. or i.v. twice weekly. Other Uses: The other options, while effective for other cancers, are not used for treating choriocarcinoma. Reference: KDT-Essentials of Medical Pharmacology, 8th Edition, Page 921",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q14_exp.png",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 15,
      "question": "A 65 y/o male is undergoing chemotherapy for the treatment of non-Hodgkin's lymphoma. During his treatment, he developed pancytopenia, characterized by anemia, leukopenia, and thrombocytopenia. The oncologist reviews the patient's medication list to determine which drug might be responsible for the patient’s lab results. All of the following drugs could be responsible for the patient’s condition except?",
      "options": {
        "A": "Cyclophosphamide",
        "B": "Methotrexate",
        "C": "Doxorubicin",
        "D": "Vincristine"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Vincristine Explanation: The patient’s pancytopenia is probably due to bone marrow suppression caused by his anti-cancer drugs. Vincristine, a vinca alkaloid, specifically targets cells during the M phase (mitosis). It binds to tubulin and inhibits microtubule formation. This disruption primarily affects cells with high mitotic activity but has a preferential effect on neural tissues due to their microtubule-dependent processes and has very little effect on bone marrow cells. Other anticancer drugs which do not cause bone marrow suppression include: Asparaginase Bleomycin Chlorambucil Cyclophosphamide (Option A) is an alkylating agent very well known to cause bone marrow suppression. MOA of Alkylating agents causing cell death: Methotrexate (Option B) is a folate analog that inhibits dihydrofolate reductase (DHFR) needed for DNA synthesis and repair, causing bone marrow suppression. Doxorubicin (Option C) causes bone marrow suppression by DNA Intercalation, Topoisomerase II Inhibition, and free radical formation causing DNA damage. MOA:",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 16,
      "question": "A 25-year-old male presents with a history of recurrent episodes of severe pain in his limbs and chest, especially during cold weather or after vigorous physical activity. His medical history reveals multiple hospital admissions for similar episodes, diagnosed as vaso-occlusive crises. Laboratory investigations confirm the presence of hemoglobin S. His physician decides to start him on a medication that helps to reduce the frequency of painful crises and the need for blood transfusions. Which of the following is the most appropriate medication for this patient's condition?",
      "options": {
        "A": "Methotrexate",
        "B": "Hydroxyurea",
        "C": "Imatinib",
        "D": "Anagrelide"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Hydroxyurea Explanation: This patient most likely has sickle cell disease and is experiencing painful vaso-occlusive crises. Hydroxyurea is the drug of choice in this scenario and it works by increasing fetal hemoglobin (HbF) levels, which helps reduce the frequency of sickle cell crises. Mechanism of Action: Hydroxyurea blocks the conversion of ribonucleotides to deoxyribonucleotides by inhibiting the enzyme ribonucleoside diphosphate reductase (RNR), thereby interfering with DNA synthesis. Hydroxyurea treats sickle cell anemia by: Increasing Fetal Hemoglobin (HbF) : Stimulates gamma-globin gene expression, reducing sickling. Lowering White Blood Cell Count : Decreases inflammation and vaso-occlusive events. Enhancing Red Blood Cell Hydration : Reduces HbS concentration and polymerization. Other Uses of Hydroxyurea: Chronic myeloid leukemia, Psoriasis, Polycythemia vera, Occasionally used in some solid tumors as a radiosensitizer before radiotherapy. Dosage of Hydroxyurea: Daily dose: 20-30 mg/kg Twice weekly dose: 80 mg/kg Methotrexate (Option A): Methotrexate is primarily used for rheumatoid arthritis and certain types of cancer. Methotrexate inhibits dihydrofolate reductase, blocking DNA synthesis by preventing the conversion of dihydrofolate to tetrahydrofolate. Imagining (Option C): Imatinib is used for chronic myeloid leukemia and gastrointestinal stromal tumors. Imatinib is a tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein in CML and other cancers, blocking signaling pathways that promote cell proliferation and survival. Anagrelide (Option D): Anagrelide is used for thrombocythemia. Anagrelide is a selective phosphodiesterase III inhibitor that reduces platelet production by inhibiting megakaryocyte maturation, thereby lowering elevated platelet counts in conditions like essential thrombocythemia. Reference: KDT-Essentials of Medical Pharmacology, 8th edition, Page 927",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 17,
      "question": "A 60-year-old male patient is diagnosed with locally advanced squamous cell carcinoma of the head and neck. His oncologist recommends a combination of radiation therapy and chemotherapy. The patient expresses concern about the potential damage to his surrounding normal tissues from the radiation. To address his concerns, the oncologist considers using both a radio-sensitizer and a radio-protector.Which of the following combinations of agents is most appropriate for this patient's treatment plan?",
      "options": {
        "A": "Cisplatin and amifostine",
        "B": "Doxorubicin and vitamin C",
        "C": "Metformin and hyperbaric oxygen",
        "D": "Gemcitabine and sodium selenite"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Cisplatin and amifostine Explanation: In the given clinical scenario, the combination of cisplatin and amifostine is appropriate. Cisplatin will enhance the radiation's impact on the squamous cell carcinoma, increasing the likelihood of tumor cell death. Meanwhile, amifostine will protect the patient's normal tissues from radiation-induced damage, thus addressing the patient's concerns about potential harm to surrounding healthy tissues. Radio-sensitizers: Agents that enhance the effectiveness of radiation therapy by making cancer cells more susceptible to the damage caused by radiation. Cisplatin is a commonly used radio-sensitizer, particularly in head and neck cancers. It works by forming DNA adducts that interfere with DNA repair mechanisms, thus increasing the likelihood of radiation-induced cell death in tumor cells. Radio-protectors: Substances used to protect normal tissues from the harmful effects of radiation. Amifostine is a well-known radio-protector that selectively protects normal tissues without shielding the tumor cells. It acts by scavenging free radicals and providing thiol groups that repair radiation-induced damage in normal cells. Doxorubicin and vitamin C (Option B): Doxorubicin has some radiosensitizing properties but is not typically used in head and neck cancers for this purpose. Vitamin C is not a recognized radio-sensitizer. Metformin and hyperbaric oxygen (Option C): Metformin has some evidence of radiosensitizing effects, especially in certain cancer types, but it is not a standard agent for this purpose. Hyperbaric oxygen is more commonly used as a radio-sensitizer but is not combined with Metformin in standard practice. Gemcitabine and sodium selenite (Option D): Gemcitabine can act as a radiosensitizer in some cancers but is not standard for head and neck cancers. Sodium selenite is not a recognized radio-protector.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 18,
      "question": "A 55-year-old male patient, who has been diagnosed with metastatic testicular cancer, has been receiving cisplatin as part of his chemotherapy regimen. After his third cycle, he reports experiencing fatigue, decreased urine output, and mild swelling in his ankles. Blood tests reveal an elevated serum creatinine level and reduced glomerular filtration rate (GFR). Which of the following is the most appropriate management step? profile.",
      "options": {
        "A": "Increase the cisplatin dosage to overcome resistance.",
        "B": "Switch to another platinum-based drug such as carboplatin, which has a similar nephrotoxicity",
        "C": "Administer i.v. hydration and consider using amifostine as a nephroprotective agent.",
        "D": "Discontinue all chemotherapy and initiate dialysis immediately."
      },
      "correct_answer": "C",
      "explanation": "agent. Correct Answer: C) Administer i.v. hydration and consider using amifostine as a nephroprotective agent. Explanation: This patient with metastatic testicular cancer, who has been receiving cisplatin and reports of decreased urine output, and mild swelling in his ankles with elevated serum creatinine level and reduced GFR likely developed cisplatin-induced nephrotoxicity. Cisplatin is known for its nephrotoxic effects, which can lead to acute kidney injury. The management of cisplatin-induced nephrotoxicity includes Adequate i.v. fluids - Chloride diuresis (Cl inactivates cisplatin) Mannitol - diuresis of inactivated cisplatin Use of nephroprotective agents like IV Amifostine (by scavenging free radicals and reducing oxidative stress) Increasing the cisplatin dosage could exacerbate the kidney damage. (Option A) Switching to carboplatin is not ideal, as carboplatin can also cause nephrotoxicity, although to a lesser extent than cisplatin. (Option B) Discontinuing all chemotherapy and initiating dialysis is too extreme without trying other nephroprotective measures first. (Option D Reference: Goodman and Gilman Pharmacological Basis of Therapeutics, 14th Edition, Page 1352",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 19,
      "question": "As a pharmaceutical researcher, you are tasked with summarizing the primary uses of platinum-based chemotherapy agents. Which of the following statements is incorrect with respect to uses of cisplatin and carboplatin? gastrointestinal tract cancers and head & neck cancers. ovarian cancer.",
      "options": {
        "A": "Carboplatin is used for the treatment of retinoblastoma along with bleomycin and vincristine.",
        "B": "Platinum compounds are used in bone tumors such as osteosarcoma.",
        "C": "Platinum compounds are combined with 5- fluorouracil & radiosensitizers for the treatment of",
        "D": "Paclitaxel, when combined with cisplatin/carboplatin, produces complete resolution in the patients of"
      },
      "correct_answer": "A",
      "explanation": "and vincristine. Correct Answer: A) Carboplatin is used for the treatment of retinoblastoma along with bleomycin and vincristine. Explanation: Carboplatin is used in retinoblastoma as a part of VEC regimen, of which bleomycin is not a component. VEC regimen for retinoblastoma - Vincristine, Etoposide, Carboplatin. Also, paclitaxel, when used with cisplatin or carboplatin induces complete responses in the majority of patients with carcinoma of the ovary. Uses of Cisplatin and Carboplatin: Gastrointestinal Tract (GIT) Cancers: Esophagus, stomach, colorectal, anal cancers Combined with 5- fluorouracil and radiosensitizers Head and Neck Cancers: (Option C) Combined with 5- fluorouracil and radiosensitizers Urogenital Cancers: Cervical Cancer Ovarian Cancer (Option D) Testicular Cancer ( BEP regimen : Bleomycin, Etoposide, Platin- Cisplatin/Carboplatin) Retinoblastoma: VEC regimen (Vincristine, Etoposide, Carboplatin) Other Uses: Osteosarcoma (Option B) Lung Cancer Paclitaxel (Option D): It inhibits microtubule disassembly during cell division, leading to cell cycle arrest and apoptosis. Cisplatin/carboplatin cross-links DNA strands, preventing DNA replication and transcription, which also leads to cell death. Thus, they act synergistically to produce complete resolution of ovarian cancer. Reference: Goodman & Gilman Pharmacological Basis of Therapeutics, 13th Edition, Page 1176 & 1177",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 20,
      "question": "Match the following drugs with their primary uses: Drug Primary Use 1. Sargramostim A. Granulocyte- CSF used in Stem cell extraction 2. Melphalan B. Granulocyte- Macrophage CSF used in Stem cell extraction 3. Plerixafor C. Used in myeloablation for bone marrow transplantation 4. Filgrastim D. Blocks CXCR4 receptor for stem cell mobilization",
      "options": {
        "A": "1-B, 2-C, 3-A, 4-D",
        "B": "1-B, 2-C, 3-D, 4-A",
        "C": "1-A, 2-D, 3-C, 4-B",
        "D": "1-A, 2-C, 3-D, 4-B"
      },
      "correct_answer": "B",
      "explanation": "marrow recovery after chemotherapy or transplant; treats severe neutropenia. MOA : GM-CSF that stimulates the production and activation of granulocytes and macrophages. Melphalan Indications : Treats multiple myeloma; used as a conditioning regimen before stem cell transplant. MOA : Alkylating agent that forms DNA cross-links, preventing replication and causing cell death. Plerixafor Indications : Mobilizes stem cells for collection in lymphoma or multiple myeloma patients. MOA : CXCR4 antagonist that disrupts the binding of stem cells to bone marrow, facilitating their release into the bloodstream. Filgrastim Indications : Prevents or treats neutropenia from chemotherapy or bone marrow disorders. MOA : G-CSF that stimulates neutrophil production and function in the bone marrow. Reference: Goodman & Gilman Pharmacological Basis of Therapeutics, 13th Edition, Page 755-756, 1173",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q20_exp.png",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 21,
      "question": "Match the following cytotoxic drugs with their primary uses: Cytotoxic Drugs Primary Use 1. Temozolomide A. Treatment of Hodgkin's lymphoma 2. Dacarbazine procedures 4. Thiotepa D. Used in cisplatin-resistant ovarian cancer cases 5. Altretamine E. Treatment of leiomyosarcoma",
      "options": {
        "B": "1-A, 2-B, 3-E, 4-D, 5-C",
        "A": "1-B, 2-A, 3-E, 4-C, 5-D",
        "C": "1-B, 2-E, 3-A, 4-D, 5-C",
        "D": "1-E, 2-C, 3-B, 4-A, 5-D"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) 1-B, 2-A, 3-E, 4-C, 5-D Explanation: Miscellaneous Alkylating agents used as Cytotoxic drugs Alkylating agents are chemotherapy drugs that attach alkyl groups to DNA, causing cross-linking, disrupting replication, and leading to cell death.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 22,
      "question": "A 60-year-old female with a history of chronic myeloid leukemia (CML) is being treated with Busulfan. She presents to the clinic with complaints of abdominal pain and swelling, fatigue, and yellowing of the skin. Additionally, the patient reports experiencing episodes of seizures since starting busulfan therapy. Upon examination, the patient has hepatomegaly and jaundice. Liver function tests indicate elevated liver enzymes. Which of the following statements is incorrect for the next steps? syndrome (Veno-Occlusive Disease)",
      "options": {
        "A": "The patient’s should be started on defibrotide as the symptoms are likely due to Budd-Chiari",
        "B": "Prompt administration of warfarin to reduce chances of another episode of VOD.",
        "C": "Patients should be started on antiepileptics such as phenytoin to prevent seizures.",
        "D": "Adjust the dose of busulfan based on plasma drug-level monitoring."
      },
      "correct_answer": "B",
      "explanation": "VOD. Correct Answer : B) Prompt administration of warfarin to reduce chances of another episode of VOD. Explanation : The patient is a typical case of Budd-Chiari like Syndrome , a type of Veno Occlusive Disease (VOD) commonly seen in the patients on busulfan. Warfarin is an anticoagulant and is not used for the treatment of VOD. Therefore, this statement is incorrect. Side effects of Busulfan includes :- Bone marrow suppression (maximum risk) Pulmonary fibrosis Seizures Budd-Chiari like syndrome Tumor lysis syndrome The patient’s should be started on defibrotide as the symptoms are likely due to Budd-Chiari syndrome (Veno-Occlusive Disease) (Option A): The management of VOD focuses on use of defibrotide which is an antithrombotic agent as the treatment of choice. Patients should be started on antiepileptics such as phenytoin to prevent seizures (Option C): Patients on Busulfan, if experiencing episodes of seizures, are to be started on phenytoin , which is the frequently used anti-epileptic for patients on Busulfan. However, Phenytoin also induces the enzymes that metabolize busulfan, reducing its plasma concentration by about 20% thus reducing its side effects. Adjust the dose of busulfan based on plasma drug-level monitoring (Option D): Adjusting the dose of Busulfan based on plasma drug-level monitoring is frequently done to balance therapeutic efficacy and minimize toxicity, especially since Busulfan clearance can vary significantly among patients. Reference: Goodman & Gilman Pharmacological Basis of Therapeutics, 13th Edition, Page 1173",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 23,
      "question": "A 55-year-old male with a history of non-Hodgkin's lymphoma is receiving chemotherapy, including cyclophosphamide. After a few weeks of treatment, he presents with symptoms of urinary frequency, urgency, and dysuria. Urinalysis reveals hematuria. The patient's physician suspects hemorrhagic cystitis. Which of the following statements is false regarding the use of cyclophosphamide? bladder epithelium. cyclophosphamide itself. toxic effects in the bladder.",
      "options": {
        "A": "Hemorrhagic cystitis is primarily caused by the direct cytotoxic effect of cyclophosphamide on the",
        "B": "Ifosfamide, a modification of cyclophosphamide, is more likely to cause hemorrhagic cystitis than",
        "C": "Cyclophosphamide is metabolized into 4-hydroxy cyclophosphamide in the liver by CYP2B6.",
        "D": "Hemorrhagic cystitis is treated by MESNA (Mercapto-Ethane-Sulfonate-Sodium,) which neutralizes"
      },
      "correct_answer": "A",
      "explanation": "cyclophosphamide on the bladder epithelium. Correct Answer: A) Hemorrhagic cystitis is primarily caused by the direct cytotoxic effect of cyclophosphamide on the bladder epithelium. Explanation: Hemorrhagic cystitis is not caused by the direct cytotoxic effect of cyclophosphamide itself. Instead, it is caused by a metabolite of cyclophosphamide, acrolein , which is excreted in the urine and irritates the bladder lining. It is characterized by painful hematuria & increased urinary frequency & urgency . Side effects of cyclophosphamide includes: Ototoxicity Hemorrhagic cystitis Cyclophosphamide is metabolized into 4-hydroxy cyclophosphamide in the liver by CYP2B6 (Option C): Cyclophosphamide is metabolized in the liver by CYP2B6 as follows: Ifosfamide, a modification of cyclophosphamide, is more likely to cause hemorrhagic cystitis than cyclophosphamide itself (Option B): Ifosfamide, a modification of cyclophosphamide, is more likely to cause hemorrhagic cystitis than cyclophosphamide, by producing higher levels of the same toxic metabolite, acrolein. Hemorrhagic cystitis is treated by MESNA (Mercapto-Ethane-Sulfonate-Sodium), which neutralizes toxic effects in the bladder (Option D): Hemorrhagic cystitis due to Cyclophosphamide/Ifosfamide is prevented by Oral MESNA and treated by i.v. MESNA , which neutralizes the toxic effects of Acrolein.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 24,
      "question": "A 65 y/o male presents with complaints of fatigue, lower back pain, and recurrent infections over the past few months. He also reports recent weight loss and increased thirst. O/E, pallor is noted. His lab investigations revealed anemia, hypercalcemia, elevated serum creatinine, hypoproteinemia, and M Spike in SPEP test. His urinalysis also showed Bence Jones proteins.Which of the following nitrogen mustard derivatives should be used in treating this patient?",
      "options": {
        "A": "Cyclophosphamide",
        "B": "Mechlorethamine",
        "C": "Chlorambucil",
        "D": "Melphalan"
      },
      "correct_answer": "D",
      "explanation": "myeloma Melphalan is a nitrogen mustard derivative specifically used to treat multiple myeloma. It works by alkylating DNA and RNA, leading to the disruption of cancer cell replication and eventually cell death. It is often used in combination with other drugs: Melphalan + Thalidomide + Dexamethasone It is also given for myeloablative procedure Cyclophosphamide (Option A), mechlorethamine (Option B) and chlorambucil (Option C): They are also nitrogen mustard derivatives used in oncology, but they are not the first line of choice for multiple myeloma. Nitrogen mustard derivatives and its uses: Nitrogen mustards Uses Melphalan (Option D) Tx of Multiple Myeloma Myeloablative procedures Mechlorethamine (Option B ruled out) Tx of Hodgkin's lymphoma ( ABVD & MOPP Regimen) Tx of cutaneous T-cell lymphoma Cyclophosphamide (Option A ruled out) DOC in Burkitt’s lymphoma Tx of other cancers eg. Breast cancer Ovarian cancer Neuroblastoma Non-Hodgkin's lymphoma Immunosuppressant in Wegener's Granulomatosis (DOC) Acute cerebral vasculitis Rheumatoid arthritis Steroid dependent nephrotic syndrome Chlorambucil (Option C ruled out) 2nd line Tx of CLL Busulfan Tx of CML and AML in resistant cases Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1349",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 25,
      "question": "A 55 y/o male presents with stage 3 lung cancer. The oncologist recommends treatment with a chemotherapy regimen that includes a cytotoxic drug known to be most effective during the S phase of the cell cycle. Which of the following cytotoxic drugs did he most likely recommend?",
      "options": {
        "A": "Vincristine",
        "B": "Cisplatin",
        "C": "5- Fluorouracil",
        "D": "Bleomycin"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) 5- Fluorouracil Explanation: Fluorouracil primarily acts on the S phase by inhibiting thymidylate synthase, an enzyme essential for DNA synthesis. Vincristine (Option A): Acts during the M phase (mitosis) by disrupting microtubule assembly. Cisplatin (Option B): Acts during all phases of the cell cycle by forming DNA adducts and inhibiting DNA repair. Bleomycin (Option D): Acts during the G2 phase of cell cycle by binding to the DNA and producing free radicals that damage the DNA. Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1352, 1356, 1363,",
      "image": null,
      "explanation_image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxpharmacology/Anticancer_Drugs-Cytotoxic_Drugs_Q25_exp.jpg",
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 26,
      "question": "A 50 y/o male was diagnosed with Hodgkin's lymphoma two years ago. He underwent chemotherapy for the same. Recently, the patient has presented with symptoms of fatigue, easy bruising, and recurrent infections. Laboratory tests and bone marrow biopsy confirmed a diagnosis of AML. Which of the following drugs used in the treatment of this patient's Hodgkin's lymphoma is most likely responsible for the development of his condition?",
      "options": {
        "A": "Doxorubicin",
        "B": "Vincristine",
        "C": "Bleomycin",
        "D": "Procarbazine"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Procarbazine Explanation: Procarbazine is an alkylating agent used in Hodgkin’s lymphoma (e.g., MOPP regimen). Alkylating agents are well known to cause therapy-related myeloid neoplasms , particularly acute myeloid leukemia (t-AML) , often with a latency of 2–10 years . The patient’s presentation of AML two years after chemotherapy strongly implicates prior exposure to an alkylator like procarbazine. Secondary Malignancies after Chemotherapy Drug Class Examples Latency to t-AML/t-MDS Mechanism of Leukemogenesis Alkylating agents Procarbazine, Cyclophosphamide 2–10 years DNA cross-linking → chromosomal aberrations Topoisomerase II inhibitors Etoposide, Doxorubicin 1–3 years MLL gene rearrangements Antimetabolites 6-Mercaptopurine, 5-FU Rare DNA synthesis interference, less leukemogenic Radiation therapy – 5–20 years DNA strand breaks → chromosomal damage Doxorubicin (Option A): Incorrect. While a topoisomerase II inhibitor and associated with t-AML, this typically occurs 1–3 years post-treatment and involves MLL rearrangements; less likely than alkylator in this context. Vincristine (Option B): Incorrect. A microtubule inhibitor not linked to secondary leukemias. Bleomycin (Option C): Incorrect. Causes pulmonary toxicity but not leukemogenic. Reference: Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1351, 1363, 1370",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    },
    {
      "q_no": 27,
      "question": "A 45 y/o male with AML has been undergoing intensive chemotherapy. Three days after starting treatment, he developed a sudden onset of weakness, nausea, and muscle cramps. Laboratory tests reveal hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia. His urine output has decreased significantly over the past 24 hours. Which of the following is not a treatment option for this patient?",
      "options": {
        "A": "Aggressive intravenous hydration",
        "B": "Allopurinol",
        "C": "Rasburicase",
        "D": "Sodium bicarbonate"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Sodium bicarbonate Explanation: The patient's symptoms and lab values suggest that he has tumor lysis syndrome. Tumor lysis syndrome occurs due to the rapid killing of cancerous cells in the blood. It is characterized by : Hyperkalemia Hyperuricemia Hyperphosphatemia Hypocalcemia Intrinsic tumor - related risk factors Patient - related risk factors High risk cancers - Burkitt lymphoma, ALL and AML (with WBC > 1 lakh), Diffuse large B cell lymphoma, etc. Pre-treatment Hyperuricemia or Hyperphosphatemia. High proliferation Rate. Pre-existing nephropathy / oliguria. Large tumor burden (> 10cm). Inadequate hydration. Chemosensitivity. Sodium bicarbonate worsens the condition by increasing the precipitation of calcium phosphate in kidneys: Sodium bicarbonate is an alkaline substance. When administered, it can increase the pH of the urine, making it more alkaline. Calcium phosphate has decreased solubility in alkaline conditions. As the urine pH rises, the solubility of calcium phosphate decreases, leading to a higher risk of precipitation. Hence, sodium bicarbonate is not given to patients with tumor lysis syndrome. Aggressive intravenous hydration (Option A): It is essential to help flush out the kidneys and reduce the risk of uric acid and calcium phosphate crystal deposition. Allopurinol (Option B): It is used to inhibit the production of uric acid, thus preventing hyperuricemia present in tumor lysis syndrome. Rasburicase (Option C): It is an enzyme that helps break down uric acid to a more soluble form (allantoin), which is easier to excrete. Reference: Tumor lysis syndrome and its treatment Goodman & Gillman Pharmacological Basis of Therapeutics, 14th Edition, Page 1405",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Anticancer Drugs-Cytotoxic Drugs"
    }
  ]
}
